Effectiveness Of Sodium Glycididazole As A Radiation-enhancing Agent In Management Of Advanced Inoperable Cases Of Lung Cancers

BackgroundLung cancer is also the leading cause of cancer mortality throughout the world with a mortality accounts for approximately28%of all cancer deaths, and an estimated mortality rate of1.3million yearly. Worldwide some1.4million new cases of this disease are diagnosed each year, accounting for12%of all cancer cases. Lung cancer is the most common cancer in China. Deaths from this typically fatal disease have shot up nearly fivefold since the1970s. The main two types of lung cancer are small cell lung cancer (SCLC) that is the most aggressive type and accounts for13-15%of cases and non-small cell lung cancer (NSCLC) that accounts for85%of cases. Surgery is the treatment of choice, but about80%of the lung cancer patients are (medically or technically) inoperable due to locoregional tumor extension, extra-thoracic spread or poor physical condition at the time of diagnosis. Hypoxia is considered as a major problem for the efficacy of radiotherapy in lung cancer patients, radiosensitizers including sodium glycididazole emerged as effective adjuvant therapy in treatment of advances lung cancer cases.MethodsWe performed a hospital based prospective descriptive study to assist the efficacy of adjuvant therapy using sodium glycididazole as radio-enhancing agents in combination of conventional chemotherapy/radiotherapy in treatment of advanced inoperable cases of lung cancers.We stared our study with38patients with advanced inoperable lung cancers (Stages ⅢA, ⅢB, and Ⅳ), which are divided into two equal groups. Group (1), composed of19patients who are received intravenous sodium glycididazole in addition to the conventional chemotherapy and radiotherapy for treatment of lung cancers. Group (2), other19patients who received only the conventional chemotherapy and radiotherapy for treatment of lung cancers. The two groups are followed on the base of clinical evaluation, radiological assessment and laboratory markers to evaluate the outcome of the treatment options. The outcome divided into three major groups based on the previous parameters to (improved-stable-worse).ResultsThe results of our study showed that14patents (73.7%), out of the19patients who received sodium glycididazole showed signs of improvement compared to6(31.6%) in the patients didn’t received sodium glycididazole.3patents (15.8%), out of the19patients who received sodium glycididazole are stable compared to4(21%) in the patients didn’t received sodium glycididazole.2patents (10.5%), out of the19patients who received sodium glycididazole are get worse compared to9(47.4%) in the patients didn’t received sodium glycididazole. The difference between the two groups was statistically significant p<0.05.ConclusionIn the present study we found a significant difference in the outcome of the advanced, inoperable cases of lung cancers when sodium glycididazole used as adjuvant therapy in combination with the conventional chemotherapy and radiotherapy.